• NIH trial: Gilead's drug works best in COVID patients on oxygen

    8 days ago - By Reuters

    The U.S. National Institutes of Health on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra oxygen but do not require mechanical ventilation.
    Read more ...

     

  • Peer-reviewed data shows Gilead's drug helps COVID-19 recovery time

    8 days ago - By Reuters

    The U.S. National Institutes of Health said on Friday peer-reviewed data published in the New England Journal of Medicine show that Gilead Sciences Inc's remdesivir is effective at helping COVID-19 patients recover.
    Read more ...

     

  • Covid-19 study details benefits of treatment with remdesivir, and also its limitations

    8 days ago - By STAT

    Remdesivir, the only drug cleared to treat Covid-19, sped the recovery time of patients with the disease, but its benefit appeared much more limited in patients who needed mechanical ventilation as part of their treatment, according to eagerly awaited results of a clinical trial.
    Initial results from the study, which led to the drug's emergency authorization by the Food and Drug Administration, were released late last month. Full data were published late Friday in the New England Journal of Medicine.
    Read more ...